Programs and Events

Myotonic Making an Impact: Report Back on Myotonic 3.0

Many Myotonic community members are aware of an important, multi-year Myotonic effort -- Myotonic 3.0: Accelerating Drug Development -- because we published an article on the launch of this initiative in early 2015. Read a full report on the first-year results of Myotonic 3.0: Accelerating Drug Development, and the initiatives we are pursuing to promote the development of new DM therapies.  

Common Symptoms of DM2 and Their Impact on Daily Living

Researchers from the University of Rochester recently published a paper examining the symptoms and impact of myotonic dystrophy type 2 (DM2). They found that the most commonly reported symptoms of DM2 are not, in fact, the ones that have the highest reported impact on daily living.

Myotonic SAC Member Profile: Dr. Kathie Bishop

Myotonic is pleased to welcome Dr. Kathie Bishop, Ph.D., to its Scientific Advisory Committee(SAC). Dr. Bishop, who joined the SAC in summer 2015, is a seasoned expert in neurological and neuromuscular research and drug development.

Community Perspectives on Future Drug Benefits and Risks

As part of our investment in the development of effective treatments for myotonic dystrophy, Myotonic is helping develop what is called "benefit/risk" information for regulatory agencies reviewing potential therapies.

Caregiving Today: Stresses, Satisfactions, and a Need for Better Solutions

In honor of National Family Caregivers Month, and to celebrate the many critically important caregivers in the Myotonic community, we’ve taken a look at the status of caregiving today. 

Myotonic 3.0

The Myotonic 3.0 Roadmap is available for your review. Myotonic has pledged our resources to a number of significant aimed at accelerating Care and a Cure for the next three years.

Myotonic Workshop Examines Clinical Trial Endpoints and Biomarkers

To support myotonic dystrophy drug development efforts, Myotonic held a science workshop in September 2014 at our annual conference. The workshop brought together more than 50 DM researchers and industry representatives from around the world to review where we are in the development of clinical trial endpoint measures for DM.

2014 MDF Annual Conference – What a Weekend!

The 2014 MDF Annual Conference, which occurred Friday, September 12 and Saturday, September 13, was a singular success, featuring oversold registration, an unparalleled number of researchers, pharma and biotech partners and federal agency representatives, and a number of impressive programmatic "firsts."

Join the Myotonic Dystrophy Family Registry

Join the Myotonic Dystrophy Family Registry and help accelerate myotonic dystrophy research and drug development! 

In Memory of Shannon Lord, MDF Founding Chairman

It is with great sadness and heavy hearts that the MDF mourns the passing of our founding chairman, Shannon Lord, who passed away on June 4, 2013.

© Myotonic Dystrophy Foundation. All rights reserved.